{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Immunology",
      "Infection",
      "SARS-CoV-2",
      "Vaccines"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33514888",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "02",
    "Day": "05"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/d41586-021-00241-6"
    ],
    "Journal": {
      "ISSN": "1476-4687",
      "JournalIssue": {
        "Volume": "590",
        "Issue": "7844",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "Nature",
      "ISOAbbreviation": "Nature"
    },
    "ArticleTitle": "How to redesign COVID vaccines so they protect against variants.",
    "Pagination": {
      "StartPage": "15",
      "EndPage": "16",
      "MedlinePgn": "15-16"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Callaway",
        "ForeName": "Ewen",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ledford",
        "ForeName": "Heidi",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "News"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nature",
    "NlmUniqueID": "0410462",
    "ISSNLinking": "0028-0836"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "trends"
      ],
      "DescriptorName": "Biotechnology"
    },
    {
      "QualifierName": [
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "adverse effects",
        "chemistry",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Design"
    },
    {
      "QualifierName": [
        "trends"
      ],
      "DescriptorName": "Drug Industry"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Immunization, Secondary"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "chemistry",
        "classification",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "chemistry",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    }
  ]
}